China: Admission Of Post-Filing Experimental Data For Inventiveness Takeda Pharmaceutical Co.,Ltd. V. Patent Reexamination Board (Article No. 21 From "China Patent Case Review 2015" By Beijing East Ip Ltd.)

Pharmaceutical Composition for Use in Diabetes Treatment

Takeda Pharmaceutical Co.,Ltd. v. PRB - Admission of Post-filing Experimental Data for Inventiveness (Administrative Ruling (2012) Zhi Xing Zi No.41 by the Supreme People's Court on September 17, 2012)

In the procedure of granting and confirming a patent right, the paten applicant/patentee may intend to submit supplementary experimental data to prove the patent has inventiveness. Admission of the post-filing experimental data should be reasonable and objective in view of the proper balance between the interests of patentees and the public. This case highlights the premise to admit the post-filing experimental data for determination of inventiveness, i.e. such data should direct to the technical effect described in the original application documents.

The patentee, Takeda Pharmaceutical Co.,Ltd. (hereinafter "Takeda"), owns a invention patent No. ZL96111063.5 titled as "Pharmaceutical Composition for Use in Treatment of Diabetes" (hereinafter "the patent concerned"). Claim 1 was "pharmaceutical composition useful for prophylaxis or treatment of diabetes, diabetic complications, glucose or lipid metabolism disorders, which comprises an insulin sensitivity enhancer selected from pioglitazone or a pharmacologically acceptable salt thereof, and Sulfonylurea as insulin sensitivity enhancers."

Sichuan Haisco Pharmaceutical Co.,Ltd.(hereinafter "Haisco"), Chongqing Institute of pharmaceutical industry Co., Ltd.(hereinafter "Chongqing Institute") filed the invalidation request with the Patent Reexamination Board (PRB) on June 13, 2008 and July 18, 2008, respectively,based on the same grounds. One of the invalidation ground is that Claim 1 lacks inventiveness. In this regard, Takeda submitted counter-evidence 7 to prove that the patent concerned had unexpected technical effect.

The PRB rendered the Invalidation Decision No. 12712 not in favor of Takeda. According to the invalidation decision, it holds Takeda's counter-evidence 7 inadmissible for authenticity and could not prove the inventiveness of claim 1.

Takeda appealed to the Beijing First Intermediate People's Court (the first instance court). Meanwhile, Takeda submitted patent examination file of the patent concerned and its European family patent, arguing the experimental data submitted in the invalidation procedure was admitted in substantive examination both by the State Intellectual Property Office (SIPO) and European Patent Office (EPO).

The first instance court decided that the counter-evidence 7 was not the original lab reports and did not show institutions or individuals of the experiments; since Haisco and Chongqing Institute did not accept the counter-evidence 7, it is legitimate for the PRB not admitting it. The second instance court affirmed.

Takeda appealed to the Supreme People's Court (SPC) for retrial. According to the SPC's ruling, Takeda's counter-evidence 7 described the specific experiment procedure and the clear result, as a unilateral proof of that the combination of pioglitazone and glimepiride has unexpected synergy. However, there is no evidence establishing that the examiner of either the SIPO or the EPO granted the patent because of the admission of the counter-evidence 7. The fact that the counter-evidence 7 existed in the related examination files can only prove that Takeda had submitted these materials in the substantive examination phase. Moreover, the counter-evidence 7 was not original and it did not show which institution or who made the experiments, nor it was notarized. At the same time, the counter-evidence 7 was not accepted by Haisco and Chongqing Institute. Thus, it was not improper for the PRB disallowing the counter-evidence 7.

Furthermore, the SPC holds that: experimental data filed after the date of filing is not contained in the original patent application document. If the technical effect of the patent was determined based on such experimental data, it would be contrary to the first-to-file principle, also violate the essence of the patent system. And it was not fair to the public to grant a patent application on this basis. When the patent applicant or patentee want to submit comparing experimental data to prove the claimed technical solution had inventiveness in respect to the prior art, the premise for admitting the data is that the experimental data should direct to the technical effect described in the original application documents.

To be specific, Takeda provided the counter-evidence 7 to prove the combination of pioglitazone and glimepiride had unexpected hypoglycemic effects compared with the effect when they are used alone or of other combination protocols. However, in the patent specification, there were only experimental results of combination of pioglitazone and voglibose, and combination of pioglitazone and glibenclamide, which claimed better hypoglycemic effect due to combination of insulin sensitivity enhancer and insulin secretion enhancer. It did not mention the effect among different combination protocols of drugs. The technical effect argued by Takeda based on the post-filing experimental data was not described in the original application documents, and awaited verification. Therefore, such experimental data cannot be used as the basis for evaluation of the inventiveness.

For the reasons above, the SPC rejected Takeda's retrial petition.


It has been a hot topic in the field of chemistry and medicine that whether supplementary experimental data submitted after the date of filing should be admitted. Chemistry and medicine are experimental science. For the inventions thereof, it is not possible to prove the inventiveness without experimental data. Sometimes, the applicant/patentee may intend to submit supplementary experimental data after filing to prove inventiveness with respect to the prior art. Admission of the post-filing experimental data should be reasonable and objective in view of the proper balance between the interests of patentees and the public.

First, the authenticity of the experimental data is a precondition. As for the post-filing supplementary experimental data, it should consider the reasons the evidence was formed by, whether it is original or a photocopy, the interests of the parties providing the evidence, etc. For an extraterritorial evidence, the notarization and authentication is important.

In this case, the source of the experimental data submitted by Takeda in invalidation procedure was not indicated, and the document was not notarized or authenticated. Therefore, since the other party did not accept the authenticity, under the Chinese laws, the PRB and the courts could not admit such evidence.

Second, if the counter-evidence 7 were notarized and proved to be true, is it possible the result would be different?

The counter-evidence 7 is post-filing experimental data. Generally, this type of data will not be admitted if it is related to the practical applicability under Article 22, Paragraph 4, enablement under Article 26, Paragraph 3, or support and clarity under Article 26, Paragraph 4 of the Chinese Patent Law, for the reason that such data cannot be derived by a skilled person from the prior art.

With respect to the determination of novelty and inventiveness, it may be different. That is to say, comparison experimental data between the patent concerned and the prior art should be allowed for submission to evaluate the inventiveness. However, the comparison experimental data should direct to the effect disclosed in the original patent application documents, or the effect derived from the existing technologies by a person skilled. In this case, the counter-evidence 7 does not satisfy this condition(s).

We can conclude that, according to the first-to-file principle and the essence of disclosure for protection of patent law, even if the authenticity of the counter-evidence 7 can be confirmed, it still cannot be used to prove the technical effect that was neither recorded in the application documents nor derived from the prior art.

In summary, when a patent applicant or patentee wishes to submit post-filing comparison experimental data to prove the inventiveness, the data should direct to the technical effect described in the original application documents clearly, because this determines whether the data can be accepted and admitted. Therefore, the applicant or patentee shall submit supplementary experimental data with caution. In addition, when drafting a patent, the effect or the desired effect should be fully explained. As for the technical effect or technical solution found after the date of filing, new or divisional application in the form of a method or a use patent can be considered.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.